Spotlight Growth
No Result
View All Result
Saturday, February 4, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

INVO BioScience, Inc. (OTC Pink: IVOB) Jumps 30.43% After Reporting Annual 2017 Financial Results

by admin
March 29, 2018
in Bio/Med/Pharma, Earnings
0
Infertility Medical Device Manufacturer 2017 Earnings

Infertility Medical Device Manufacturer 2017 Earnings

INVO BioScience, Inc. (OTC Pink: IVOB) is engaged as a medical device developer for treatment of infertility. Shares of the infertility medical device company are rallying 30.43%, through early trading on Thursday, March 29, 2018. Over the past month, INVO BioScience, Inc. has seen average daily volume of 102,813 shares. However, volume of 85,673 shares or dollar volume of $46,263, has already exchanged hands on the day.

Shares of INVO BioScience, Inc. are climbing 30.43% on Thursday, after the company reported its annual 2017 financial results. During full-year 2017, the medical device company saw revenue of $282,000, compared to $51,000 in 2016. This gives the company 2017 revenue growth of 453%. Gross margins shot up to 82% and the overall net loss improved to $702,000, compared to its net loss of $2.12 million in 2016. Here is the full press release detailing of the annual 2017 financial results:

INVO BioScience, Inc. Press Release:

MEDFORD, Mass., March 29, 2018 /PRNewswire/ — INVO Bioscience, Inc. (OTC: IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced its year end 2017 financial results and recent highlights.

https://mma.prnewswire.com/media/344704/invo_logo_Logo.jpg

Financial Results and Recent Highlights:

  • Revenue for the year ended December 31, 2017 was $282,000, an increase of 453% compared to $51,000 for the same period a year ago;
  • Gross margins continued to improve during 2017 to 82% compared to 70% in 2016;
  • Net loss improved to $(702,000) during 2017 compared to $(2,124,00) in 2016 as the Company increased revenues and decreased expenses;
  • The Company has now signed up clinics in 17 states and 1 province offering or referring the INVOcell device and procedure;
  • 11 new clinics signed up offering or referring the INVOcell device and procedure since the last earnings report;
  • In February 2018, announced a distribution agreement for developing the markets in Hong Kong and Macao for INVOcell; and
  • In March 2018, expanded the Company’s certified training locations for Reproductive Endocrinologists and Embryologists to learn about the unique techniques of the simplified INVOcell Procedure, with the addition of new centers in San Antonio, Texas and South Carolina.

Management Discussion
“2017 was an incredibly successful year for INVO Bioscience,” commented Katie Karloff, Chair and Chief Executive Officer of INVO Bioscience. “On a limited operating budget, we significantly increased the awareness and acceptance of the INVOcell device and procedure. INVOcell is now available in 17 states and 1 province across the United States and Canada, and we have recently signed a distribution agreement to expand into Hong Kong and Macao. We have enhanced our infrastructure to include two additional training centers, and have strengthened our board of directors with experienced financial and industry executives. I am proud of the accomplishments in 2017 and am focused on the continued growth of this exciting new technology.”

2017 Financial Results
Net sales and revenues for year ended December 31, 2017 were approximately $282,000 compared to approximately $51,000 for the same twelve-month period ended December 31, 2016.

Cost of goods sold for the twelve months ended December 31, 2017 were $52,000 or approximately 18% of revenues compared to $15,000 or approximately 30% of revenues for the year ended December 31, 2016. The Company believes the 2017 costs of goods sold are more representative of the expectations for what our costs will be as we move forward as the company continually is taking steps to lower their costs and improve gross margin while delivering high quality products.

Selling, general and administrative expenses were $870,000 in fiscal 2017, a decrease of $1,275,000 for the year ended December 31, 2017 compared to the year ended December 31, 2016 of $2,146,000. Cash utilized during the year for operating activities was $180,000, as the company’s executive management team continued to defer salaries and other expenses were kept to a minimum.

Net loss for the year was $(702,000), or $(0.00) per share, compared with $(2,124,000), or $(0.02) per share a year ago.

Additional details pertaining to the quarterly financials can be found in our 10-K filed today with the SEC.

About INVO Bioscience

We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit http://invobioscience.com/

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Tags: 2017 earningsbiopharmaceuticalsbiotechcommon stockearningsemerging growthFDAinfertilityinvestmentmanufacturingmedicalmedical devicemicrocap stockspharmaceuticalspublic companysalessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stockstechtechnology stockstreatment
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Can the AI Boom Rebuild Investor Enthusiasm for Upstart Holdings NASDAQ UPST Spotlight Growth

Can the AI Boom Rebuild Investor Enthusiasm for Upstart Holdings (NASDAQ: UPST)?

February 3, 2023
Nerdy NYSE NRDY New AI Products Lesson Plan Creator Chat Tutor Spotlight Growth

Nerdy (NYSE: NRDY) Unveils New AI Tools for Lesson Plan Creation and Chat Tutoring

February 3, 2023
Elys Game Technology Corp NASDAQ ELYS Completes Acquisition of Engage IT Services Spotlight Growth

Elys Game Technology Corp (NASDAQ: ELYS) Completes Acquisition of Engage IT Services, a Software Engineering and IT Development Company

February 2, 2023
Tenax Therapeutics NASDAQ TENX US Patent Levosimendan PH-HFpEF Spotlight Growth

Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

February 2, 2023
ADVERTISEMENT

Recent News

Can the AI Boom Rebuild Investor Enthusiasm for Upstart Holdings NASDAQ UPST Spotlight Growth

Can the AI Boom Rebuild Investor Enthusiasm for Upstart Holdings (NASDAQ: UPST)?

February 3, 2023
Nerdy NYSE NRDY New AI Products Lesson Plan Creator Chat Tutor Spotlight Growth

Nerdy (NYSE: NRDY) Unveils New AI Tools for Lesson Plan Creation and Chat Tutoring

February 3, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested